This review concluded that prophylactic treatment with ursodeoxycholic acid appears to prevent hepatic veno-occlusive disease in patients having haematopoietic stem cell transplantation. The review was generally well conducted, but the uncertain quality of the included studies casts some doubt on the reliability of the conclusions.
Authors' objectives
To determine the prophylactic effect of ursodeoxycholic acid (UA) for the prevention of hepatic veno-occlusive disease (HVOD) in patients undergoing haematopoietic stem cell transplantation (HSCT).
Searching MEDLINE (1966 MEDLINE ( to 2006 , EMBASE (1980 EMBASE ( to 2006 , EBM Reviews (2005) and HealthSTAR (via Ovid, 1966 (via Ovid, to 2006 . Google Scholar was used to identify grey literature. To identify additional studies, the drug manufacturer and clinical experts were contacted and references in selected articles were checked. Published studies (including journal articles, conference proceedings and abstracts) in any language were eligible for inclusion. The strategy used to search MEDLINE was reported.
Study selection Study designs of evaluations included in the review
Controlled clinical trials were eligible for inclusion.
Specific interventions included in the review
Studies of UA prophylaxis were eligible for inclusion. The included studies compared UA alone or in combination with multivitamins with no treatment, or UA plus heparin with heparin alone. Oral UA was given in doses of 600 or 900 mg per day or 12 or 15 mg/kg per day. Where reported, treatment was started between 1 and 21 days before transplantation and continued until day 27, 30 or 80. Conditioning regimens variously included chemotherapy, total body and total lymphoid irradiation.
Participants included in the review
Studies in patients undergoing HSCT were eligible for inclusion. Children and adults and patients undergoing allogeneic and autologous HSCT were included. Where reported, a small number of participants had increased liver function tests and previous liver disease. Almost a third of the patients in one study had previously had chemotherapy.
Outcomes assessed in the review
Studies that reported HVOD or VOD, overall survival, transplant-related mortality or hepatic graft-versus-host disease (GVHD) were eligible for inclusion. Studies that reported only on biochemical tests were excluded. The primary outcome in the review was HVOD, defined as weight gain or fluid accumulation, elevated bilirubin and abdominal pain. The included studies used similar definitions of HVOD. The reported secondary outcomes were overall survival (more than 100 days), transplant-related mortality (death within 100 days of HSCT), acute hepatic GVHD and relapse. Where reported, follow-up varied between 100 days and more than 4 years or was reported as a mean of 42 months or a median of 182 days.
How were decisions on the relevance of primary studies made? Two reviewers applied the inclusion criteria independently and there were no disagreements.
